Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
AVBPthis companyArriVent BioPharma, Inc.	$13.98	-4.66×	2.52×	0×	-4.38×	-92.2%	0.0%	0.0%	0.0%	-54.1%	-57.8%	-20.8%	0×	0.27×	0×	12.83×	0.0%	2	12.15	2	C+
BDTXBlack Diamond Therapeutics, Inc.	$1.84	6.23×	1.23×	1.97×	5.99×	520.8%	99.5%	28.4%	32.0%	19.9%	15.2%	21.4%	0.17×	-0.1×	0×	8.42×	0.0%	1	-3.44	3	B-
ERASErasca, Inc.	$15.04	-8.45×	3.24×	0×	-8.47×	-99.3%	0.0%	0.0%	0.0%	-38.3%	-35.3%	-9.1%	0.14×	0.22×	0×	10.04×	0.0%	1	35.36	1	C-
EXELExelixis, Inc.	$70.08	15.13×	5.48×	5.1×	12.5×	124.2%	96.4%	37.6%	33.7%	36.2%	29.7%	7.1%	0.08×	-0.34×	0×	3.56×	0.0%	6	18.06	4	A
IDYAIDEAYA Biosciences, Inc.	$31.52	-27.01×	2.99×	13.99×	-19.22×	-438.0%	-43.9%	-72.8%	-52.0%	-11.1%	-15.2%	-2.4%	0.03×	0.55×	0×	11.34×	0.0%	1	14.74	2	C
NUVBNuvation Bio Inc.	$4.27	-14.93×	10.01×	48.65×	-15.36×	-33.1%	86.6%	-338.7%	-325.3%	-66.9%	-41.0%	-5.7%	0.03×	0.81×	-15.57×	6.95×	0.0%	3	0.52	1	C-
Peer median	—	-8.45×	3.24×	5.1×	-8.47×	-33.1%	86.6%	0.0%	0.0%	-11.1%	-15.2%	-2.4%	0.08×	0.22×	0×	8.42×	0.0%	1	14.74	2	—